Vaccinex, Inc.
VCNX · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $601 | $570 | $100 | $900 |
| % Growth | 5.4% | 470% | -88.9% | – |
| Cost of Goods Sold | $0 | $0 | $207 | $169 |
| Gross Profit | $601 | $570 | $68 | $731 |
| % Margin | 100% | 100% | 68% | 81.2% |
| R&D Expenses | $12,545 | $16,574 | $13,979 | $17,160 |
| G&A Expenses | $6,791 | $6,881 | $6,202 | $6,230 |
| SG&A Expenses | $6,791 | $6,881 | $6,202 | $6,230 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$175 | -$169 |
| Operating Expenses | $19,336 | $23,455 | $20,006 | $23,221 |
| Operating Income | -$18,735 | -$22,885 | -$19,906 | -$22,490 |
| % Margin | -3,117.3% | -4,014.9% | -19,906% | -2,498.9% |
| Other Income/Exp. Net | $101 | $2,634 | $91 | $110 |
| Pre-Tax Income | -$18,634 | -$20,251 | -$19,815 | -$22,380 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18,634 | -$20,251 | -$19,722 | -$22,380 |
| % Margin | -3,100.5% | -3,552.8% | -19,722% | -2,486.7% |
| EPS | -8.88 | -43.68 | -97.59 | -163.8 |
| % Growth | 79.7% | 55.2% | 40.4% | – |
| EPS Diluted | -8.88 | -43.68 | -97.59 | -162.91 |
| Weighted Avg Shares Out | 2,099 | 464 | 202 | 137 |
| Weighted Avg Shares Out Dil | 2,099 | 464 | 202 | 137 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $1 | $2 | $809 |
| Depreciation & Amortization | $94 | $119 | $207 | $169 |
| EBITDA | -$18,538 | -$19,748 | -$19,606 | -$21,402 |
| % Margin | -3,084.5% | -3,464.6% | -19,606% | -2,378% |